Asciminib With or Without Sildenafil for Brain Tumors (NCT07039760)
An Early Phase 1 Study of Asciminib With or Without Sildenafil for Brain Tumors
🩺 Plain-English Summary (8th-Grade Level)
Dissemination of medulloblastoma is an independent risk factor of poor prognosis. Dissemination of medulloblastoma at recurrence is nearly universally fatal. ABL1 and 2 have been recently found to mediate the dissemination of medulloblastoma. Genetically inactivating ABL1 and 2 resulted in decreased leptomeningeal medulloblastoma and improved overall survival (OS) in rodent models. ABL kinases have also been shown to play a role in the malignant properties of glioblastoma. Asciminib is an FDA approved for the treatment of chronic myeloid leukemia and is well tolerated, likely due to its specificity for ABL1 and ABL2. Asciminib is a P-glycoprotein (P-gp) substrate and thus may be susceptible to being pumped out of tumor cells and brain endothelial cells. It is unclear if asciminib can enter the central nervous system (CNS) and brain tumors in adequate concentration to have anti-tumor effects.
Who can join: Review the eligibility criteria below.
Location: Washington University School of Medicine/St. Louis Children's Hospital — St Louis, Missouri
Age range: 18 Years to 39 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Washington University School of Medicine/St. Louis Children's Hospital — St Louis, Missouri
📞 Contact the Study Coordinator
Phone: (314) 454-4707
Email: pedshemonctrialreferral@wustl.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Brain Tumor
- Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound — Toronto, Ontario
- Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study — Memphis, Tennessee
- Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors — Hartford, Connecticut
- Understanding the Late Effects of Surviving a Pediatric Brain Tumor — New York, New York
- Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG — Toronto, Ontario
- Observational Trial of the Impact of Radiation Dose in Children With Brain and Skull Base Tumors. — Miami, Florida
Explore by condition: All Brain Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.